Clinical Trial Update: Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) [Phase 3]

View source ↗

Summary

Phase 3 studies evaluating Sarepta's Casimersen (SRP-4045) and Golodirsen (SRP-4053) in Duchenne Muscular Dystrophy have completed; results are not detailed in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• AMONDYS 45 (Casimersen)
• VYONDYS 53 (golodirsen)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: COMPLETED